A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ) over the past three months, with a range of price targets and recommendations. The average price target has decreased by 3.36% to $166.92. Jazz Pharmaceuticals has shown positive revenue growth but lags behind industry peers, with strong net margins and effective debt management.
August 19, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Jazz Pharmaceuticals has received mixed analyst ratings, with a decrease in the average price target by 3.36% to $166.92. The company shows positive revenue growth but lags behind industry peers. Strong net margins and effective debt management are noted.
The mixed analyst ratings and decrease in average price target suggest a neutral short-term impact on JAZZ's stock price. Positive financial metrics like net margins and debt management are offset by lagging revenue growth compared to peers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100